(Infectious disease clerkship)

(pharmaceutical care)

	team)	care
	. (patient profile) SOAP note	
	. (drug therapy problems)	
	. (discharge counseling)	
	 Drug product selection Pharmacokinetic and drug dosage regimen Drug interactions and adverse drug effects Pharmacotherapeutic monitoring plan Drug administration 	
•	discharge counseling note, pharmacokinetic note, medication history no patient transfer note	ote,

Laboratory tests to direct antimicrobial pharmacotherapy

Specific and non-specific tests confirming the presence of infection (e.g., WBC count and differential, gram stain, culture), quantitative and qualitative antimicrobial susceptibility testings (e.g., MIC, E-test),

. Antimicrobial regimen selection

Systematic approach for selection of antimicrobials, drug factors, combination antimicrobial therapy, monitoring therapeutic response

. Central nervous system infections

Meningitis, brain abscess

. Respiratory tract infections

Upper and lower respiratory tract infections (e.g., bronchitis, pneumonia, sinusitis)

- . Infectious endocarditis
- . Tuberculosis
- Gastrointestinal infections and enterotoxigenic poisonings
- Skin and soft tissue infection

Cellulitis, diabetic foot infection

. Parasitic infections

Malaria

Intraabdominal infections

Bacterial peritonitis, cholecystitis, cholangitis

- Urinary tract infections and prostatitis
- Bone and joint infections

Osteomyelitis, septic arthritis

- . Sepsis and septic shock
- . Invasive fungal infections

Aspergillosis, candidemia

Human immunodeficiency virus infection and opportunistic infections

AIDS, Pneumocystis jiroveci Pneumonia, cryptococcal meningitis, candidiasis, histoplasmosis, toxoplasmosis, penicillosis

•

•

-	
-	
*	
-	
_	
,	
-	
_	
-	
-	
1	
-	
- (journal club)	
/	
I	
-	
_	
- (academic in-service)	
_	
1	
-	
-	
-	
-	
-	

• *

((- / /) - / / /)
(Formal case	presentation)
(Academic	c in-service)
(Journ	al Club)
:- formal case presentation () Lab Hospital course ()	CC, HPI, PMH, FH, SH, ALL, MH, PE
()	
-	

•	(patient care round, ward round, pharmacy round)				
•	(<u>></u>	/ *	- / - /	
•	·	<u>≥</u>	/	- /	
	(case discussion)**	<u>></u>	1		
	(formal case presentation)	<u>></u>		- / - / - /	
	(academic in-service)	>	()	-	
	(journal club)	<u>></u>		- / - / - /	

*

**

case discussion

-

_

•••••	•••••	••••••
		•••••
		()
. (patient		
care round or ward round)		
care round or ward round)	,	
	/	
	/	
()		
\ /	\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \	
(agga diaguasian)	<u>></u> /	
(case discussion)		
. (formal case presentation)	<u>></u>	
	<u>></u> ()	
(, ,	
,		
)	-	
(academic inservice)		
. (journal club)	<u>></u>	
()		
,		
. *		
:		
<i>I</i>		
		••••••

ı			1		/
	•••••••••••••••••••••••••••••••••••••••	······································	••••••	/	•••••••
	(x))		1
	/				
	1			1	

- - /

•••••• ••••• ••••• ••••• x)/ 1

(_____)

1	•••	••••••	••••••	•••••	••••••
	•••••	••••••	•••••	•••••••••••••••••••••••••••••••••••••••	•••••
				1	
			1		
		(x) ()		/
		1	/		
		,			
			1		
		1	1		
		/	1		
		/	1		

N/A N/A (subjective & objective data) (Indication, Efficacy, Safety, Adherence, Cost)

			1	, ,					
					N/A			N//	
		1		, ,				, ,	
. /									
: pharmacist note,									
·									
· . :									
. /									
1									
(x)/	-			!	T	 	<u> </u>	1 [

1			
	***************************************	••••••	
	()	

1			•••••				
		•••••••••••••••••••••••••••••••••••••••		•			
	(x))	1				

	1			/
		(critical point)		
	/		/	
	/			
	/			
	/			

1	••••••	•••••	•••••	•••••	•••••	•••••	
•••••	••••••	••••••	••••••	••••• I	•••	•••••	•
							N1//
							N/A
•	CC, HPI, PMH, FH, SH, ALL, M	ILI DE Lah					T
•	CC, HEI, FIVIH, HII, SH, ALL, IV	III, FL, LAD					-
•			x .)/				
			^ · JI				
•							$\overline{1}$
•		,					-
(subjective & objective	tive data)						
	aro dataj			<u> </u>			
							T
		(IESAC)					
	1 1 1	/					
		(x)/				
•							
•							
		(x .)/				
•						1	
•						-	-
						-	+
		(x .)/				
		(^ · //				

-	-	/	

			N/A
•			
•	/ Pharm D.		
·			
	(x .)/	
•	(x)/	
	(x)/		
1			
	()	

			 •
	(x))	1
	/		
	/		
	1		
	1		
	/		

		T		
				N/A
. 1				
1				
•		1	1	
· · · · · · · · · · · · · · · · · · ·				
	(drop out)			
<u>.</u>				
-				
	(outcome variables & outcome			+
measurement)	(outcome valiables & outcome			
•				
-				
-				
. /				
•				

				·			
							N/A
	:						
•							
/	Pharm D.						
		(x/) /				

1	
	(

••••••			 		
					N
•					
•					
•					
•					
. :					
•	 				
		, 1		1 1	
Pharm D.		/			
•					
	 x)/				
_	 				
1					
,	 	 	 	••••••	••••
	 	 	 •••••	••••••	•

(demo	graphic of requestor)		E-mail a	address
/ 9 9	q q	/	q q	
q q q	(p	oatient-specific 9 9	question)	
q q q (reque	/ web site / web board est) (initial question)	q q e-mail q	q	
	(background i	nformation)		
	(ultim	nate question)		

(classification of the ultimate question)

	,
q General product information	q Adverse effects
Availability of dosage forms	q Compounding
q Dietary supplement	O Dosage recommendations
	(general and organ impairment)
q Drug interactions	Orug-laboratory interference
q Drugs in pregnancy and in	q Foreign drug identification
lactation	
q Geriatric dosage	q Identification of product by
recommendations	description of dosage form
q Investigational drug information	q Compatibility / stability
q Method / rate of administration	q Pediatric dosage
	recommendations
q Pharmacokinetics	q Pharmacology

(search strategy and conduct on systematic search)*

••••	
•••••	

•	
•	
·	
	(reywords)
	· · · · · · · · · · · · · · · · · · ·

.....

C	` ,	q	
C	1	q e-mail	
C	web site / web board	q	
			•
	(Follow up and	d follow through)	
	•		
	1	•••••	
		••••••	•••••••••••••••••••••••••••••••••••••••
:			
- Stanov	ich IF (Eds). Drug Information: a g	systematic approach Mal uide for pharmacists, Third Edition. Si	one PM, Kier KL., and
	ich, J.E. (Eus). Drug information: a g il Publishing Division.	uiue ioi pilaitilausis, ttiilu luilioti. Si	nyapore. Ivicoraw-tiin,
_ *			

(.)

-			
-			
-			
-	/		
-	/		
-			
-			
-			
-			
- /	- /		
- 1	- /	- 1	
- 1	- 1	- /	
- 1	- /	- /	